Indivior Pharmaceuticals (INDV) drew fresh attention on 29 October 2026 after reporting stronger Q3 and year to date earnings, while also reaffirming full year 2026 net revenue guidance of US$1,295 million to US$1,365 million.
At a share price of US$35.37, Indivior Pharmaceuticals has seen modest near term share price gains, and the 1 year total shareholder return of 13.37% and 5 year total shareholder return of 95.96% point to momentum that has built over a longer horizon as recent earnings and reaffirmed guidance reshape how investors weigh its growth prospects and risks.
Scan how Indivior Pharmaceuticals compares with other specialty healthcare plays that are showing improving earnings momentum by reviewing our curated list of 19 high quality undiscovered gems.
After that earnings jump and with the share price still some way below analyst targets, the puzzle for Indivior Pharmaceuticals investors is simple. Has most of the rerating already happened, or is the valuation still playing catch up?
Most Popular Narrative: 30% Undervalued
On the most followed narrative, Indivior Pharmaceuticals screens as undervalued, with a fair value estimate of about $50.83 against the recent $35.37 close. This puts the spotlight on what might be powering that gap.
The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.
See why 5 investors see Indivior Pharmaceuticals as 30% undervalued.
Result: Fair Value of $50.83 (UNDERVALUED)
Still, the bullish Indivior Pharmaceuticals story relies on SUBLOCADE execution and cost savings landing as planned. Any stumble there could quickly challenge the undervalued thesis.
Find out about the key risks to this Indivior Pharmaceuticals narrative.
Next Steps
Mixed signals in the Indivior Pharmaceuticals story so far, so treat this as a starting point and move quickly to form your own view by weighing its 5 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Indivior Pharmaceuticals?
If you stop with Indivior Pharmaceuticals, you only see part of the opportunity set. Widen your search now before others move first on the rest.
- Target potential future compounders early by scanning for quality stocks that trade below estimated value through our curated 36 high quality undervalued stocks.
- Focus on companies with resilient finances to help manage downside risk using the carefully filtered 29 resilient stocks with low risk scores.
- Prioritise balance sheet strength and solid fundamentals by running your filters through the focused list of solid balance sheet and fundamentals (24 results).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com